ReviewFrontiers in bioengineering and biotechnology2026
Microneedle-based transdermal delivery systems for metabolic bone diseases: advances, challenges, and future perspectives.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dissolving microneedles for inflammatory diseases: Advances in formulation strategies and therapeutic applications.International journal of pharmaceutics: X · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic bone diseases (MBDs), such as osteoporosis and rickets, present significant clinical challenges due to the chronic nature of treatment and the limitations of conventional systemic therapies. Oral medications often suffer from low bioavailability and gastrointestinal intolerance, while injectable biologics are hampered by poor patient adherence. Microneedle (MN) systems have emerged as a transformative transdermal delivery platform capable of overcoming these barriers. This review provides a comprehensive overview of MN technology, detailing its classification, material properties, and advantages in bypassing the stratum corneum for painless administration. We analyze how MNs have evolved from physical conduits into intelligent therapeutic platforms that integrate bone-targeting ligands, stimuli-responsive release mechanisms, and immunomodulatory functions to precisely regulate the bone microenvironment. Furthermore, we summarize recent preclinical advances in MN applications for MBDs, highlighting their ability to improve pharmacokinetic profiles and therapeutic efficacy. Finally, the review critically examines current hurdles regarding manufacturing, safety, and clinical translation, and offers perspectives on next-generation systems that combine diagnostic sensing with adaptive therapy to realize personalized bone health management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.